Phased Reduction of Cyclosporine Combined with Mycophenolate Mofetil in Renal Transplant Recipients: Three-year Results of a Prospective Study.
- Author:
Jinmo KANG
1
;
Yang Jin PARK
;
Jongwon HA
;
Taeseung LEE
;
Jungkee CHUNG
;
Yon Su KIM
;
Curie AHN
;
Sang Joon KIM
Author Information
1. Department of Surgery, Gacheon Medical School, Gil Medical Center, Incheon, Korea.
- Publication Type:Original Article
- Keywords:
Cyclosporine reduction;
Mycophenolate mofetil;
Kidney transplantation
- MeSH:
Azathioprine;
Cohort Studies;
Cyclosporine;
Immunosuppression;
Kidney Transplantation;
Mycophenolic Acid;
Prospective Studies;
Rejection (Psychology);
Transplants
- From:Journal of the Korean Surgical Society
2008;74(4):248-254
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Although cyclosporine (CsA) improves short-term renal graft outcomes, many paradigms reduce or withdraw this drug because of its nephrotoxicity. However, inadequate immunosuppression with azathioprine led to little success. We conducted a prospective study to define the prolonged effect of CsA reduction in stable renal transplant recipients with mycophenolate mofetil (MMF). METHODS: Thirty-nine primary renal transplant recipients were divided into two cohorts, the AZA (N=13) and the MMF cohort (N=26). Both cohorts were allowed to reduce the CsA dose up to 50% of baseline within 3 to 4 months of conversion to AZA or MMF. Graft function, clinical parameters, and adverse events were monitored for up to 3 years. RESULTS: Ccr gradually deteriorated in the AZA cohort, but was stable in the MMF cohort. There was no episode of acute rejection or graft loss observed in either cohort. CONCLUSION: The CsA dose can be reduced in combination with MMF treatment in stable renal transplant recipients after 2 years of transplantation, resulting in beneficial effects on Ccr, lipid profiles, and blood pressure.
